Enhanced zinc consumption prevents cadmium-induced alterations in lipid metabolism in male rats.
It has been investigated, based on a rat model of human exposure to cadmium (Cd), whether zinc (Zn) supplementation may prevent Cd-induced alterations in lipid metabolism. For this purpose, the concentrations of free fatty acids (FFA), phospholipids (PL), triglycerides (TG), total cholesterol (TCh), and high and low density lipoprotein cholesterol (HDL and LDL, respectively) as well as the concentrations of chosen indices of lipid peroxidation such as lipid peroxides (LPO), F2-isoprostane (F2-IsoP) and oxidized LDL (oxLDL) were estimated in the serum of male Wistar rats administered Cd (5 or 50mg/l) or/and Zn (30 or 60mg/l) in drinking water for 6 months. The exposure to 5 and 50mg Cd/l resulted in marked alterations in the lipid status reflected in increased concentrations of FFA, TCh, LDL, LPO, F2-IsoP and oxLDL, and decreased concentrations of PL and HDL in the serum. The concentrations of LDL, LPO, F2-IsoP and oxLDL were more markedly enhanced at the higher Cd dosage. The supplementation with Zn during the exposure to 5 and 50mg Cd/l entirely prevented all the Cd-induced changes in the serum concentrations of the estimated lipid compounds and indices of lipid peroxidation, except for the F2-IsoP for which Zn provided only partial protection. Based on the results it can be concluded that Zn supplementation during exposure to Cd may have a protective effect on lipid metabolism consisting in its ability to prevent hyperlipidemia, including especially hypercholesterolemia, and to protect from lipid peroxidation. The findings seem to suggest that enhanced dietary Zn intake during Cd exposure, via preventing alterations in the body status of lipids may, at least partly, protect against some effects of Cd toxicity, including oxidative damage to the cellular membranes and atherogenic action. The paper is the first report suggesting protective impact of Zn against proatherogenic Cd action on experimental model of chronic moderate and relatively high human exposure to this toxic metal.
Rogalska
Joanna
J
Department of Toxicology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland. asiarogalska@op.pl
Brzóska
Małgorzata M
MM
Roszczenko
Alicja
A
Moniuszko-Jakoniuk
Janina
J
D000818:Animals; D019256:Cadmium Chloride / Q000633:toxicity*; D018890:Chemoprevention; D002712:Chlorides / Q000008:administration & dosage*; D002784:Cholesterol / Q000097:blood; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004326:Drinking; D004359:Drug Therapy, Combination; D005230:Fatty Acids, Nonesterified / Q000097:blood; D015386:Hazardous Substances / Q000633:toxicity*; D006949:Hyperlipidemias / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control; D007668:Kidney / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D015227:Lipid Peroxidation / Q000187:drug effects* / Q000502:physiology; D008297:Male; D010743:Phospholipids / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood; D017967:Zinc Compounds / Q000008:administration & dosage*
D002712:Chlorides; D005230:Fatty Acids, Nonesterified; D015386:Hazardous Substances; D010743:Phospholipids; D014280:Triglycerides; D017967:Zinc Compounds; C016837:zinc chloride; D002784:Cholesterol; D019256:Cadmium Chloride